NCT00094627
Completed
Phase 3
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Adult Patients With Primary Insomnia
ConditionsPrimary Insomnia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Primary Insomnia
- Sponsor
- H. Lundbeck A/S
- Enrollment
- 465
- Primary Endpoint
- Amount of time spent awake and time to fall asleep at night after 2 days
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The purpose of the study is to test the safety and effectiveness of the Investigational Drug on insomnia.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients with a diagnosis of primary insomnia and in good physical and mental health
Exclusion Criteria
- •Adult patients with other medical , neurological and sleep disorders
Outcomes
Primary Outcomes
Amount of time spent awake and time to fall asleep at night after 2 days
Time Frame: After 2 days
Secondary Outcomes
- Amount of time spent awake and time to fall asleep at night after 30 days(After 30 days)
- Amount of deep sleep after 2 days(After 2 days)
Similar Trials
Completed
Phase 2
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)Alzheimer's DiseaseNCT00420420Merck Sharp & Dohme LLC144
Completed
Phase 2
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic PainPainDiabetic NeuropathiesNCT00375960Vernalis (R&D) Ltd50
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B VaccineHepatitis B, ChronicNCT04289987CHA Vaccine Institute Co., Ltd.134
Completed
Phase 2
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.AsthmaNCT00398645GlaxoSmithKline648
Completed
Phase 2
Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.AsthmaNCT00600171GlaxoSmithKline614